HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT05029973
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • HAIC — DRUG
    hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment
  • Sintilimab — DRUG
    200mg IV d1,Q3W
  • Bevacizumab Biosimilar — DRUG
    7.5mg/kg IV d1,Q3W

Study Details

To Evaluate the Efficacy and Safety of the Hepatic Arterial Infusion Chemotherapy(HAIC) Combined With Sintilimab and Bevacizumab Biosimilar in the Treatment of Patients With Unresectable Hepatocellular Carcinoma.

Key Dates

First listed
Sep 1, 2021
Start date
May 10, 2021
Status verified
Dec 2022
Primary completion
Jan 10, 2022
Completion
Nov 10, 2023

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Group
    HAIC Combined With Sintilimab and Bevacizumab Biosimilar

Primary Outcome Measure

Overall response rate ( ORR) [ Time Frame: Up to 2 years ]

Central Contacts

Related Studies